Europe persistent corneal epithelial defects treatment market is projected to register a substantial CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Europe persistent corneal epithelial defects treatment market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others), Type (Devices, Medication), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland and Rest of Europe) Market Trends and Forecast to 2027.

Some of the major factors contributing to the growth of the market are:
- Increase in Research and development in persistent corneal epithelial defects treatment
- Rising cases of eye surgeries and usage of contact lenses.
Market Players:

The key market players for Europe persistent corneal epithelial defects treatment market are listed below:

- Dompé Farmaceutici S.p.A
- Novartis AG
- Allergan
- Next Biosciences
- Katena Products. Inc.
- Johnson & Johnson Services, Inc.
- Hunt Valley PharmaLAB
- Laboratoires THEA S.A.S
- Skye Biologics Inc.
- I-MED Pharma inc.
- Almirall, S.A
- Ocular Science, Inc.
- Kala Pharmaceuticals
- Bausch Health
- Integra LifeSciences Corporation
- BioTissue (A Subsidiary of TissueTech, Inc.)